136 related articles for article (PubMed ID: 38621326)
21. Detection of circulating tumor human papillomavirus DNA before diagnosis of HPV-positive head and neck cancer.
Rettig EM; Faden DL; Sandhu S; Wong K; Faquin WC; Warinner C; Stephens P; Kumar S; Kuperwasser C; Richmon JD; Uppaluri R; Varvares M; Sethi R; Hanna GJ; Sroussi H
Int J Cancer; 2022 Oct; 151(7):1081-1085. PubMed ID: 35262203
[TBL] [Abstract][Full Text] [Related]
22. Histologic identification of human papillomavirus (HPV)-related squamous cell carcinoma in cervical lymph nodes: a reliable predictor of the site of an occult head and neck primary carcinoma.
El-Mofty SK; Zhang MQ; Davila RM
Head Neck Pathol; 2008 Sep; 2(3):163-8. PubMed ID: 20614311
[TBL] [Abstract][Full Text] [Related]
23. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
Lewis D; Wong WWL; Lipscomb J; Horton S
Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
[TBL] [Abstract][Full Text] [Related]
24. Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
Chen MM; Colevas AD; Megwalu U; Divi V
Oral Oncol; 2018 Sep; 84():71-75. PubMed ID: 30115479
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of comorbidities and effect on survival in survivors of human papillomavirus-related and human papillomavirus-unrelated head and neck cancer in the United States.
Eytan DF; Blackford AL; Eisele DW; Fakhry C
Cancer; 2019 Jan; 125(2):249-260. PubMed ID: 30444527
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome of head and neck cancer patients: a comparison between ENT patients referred via the 2 weeks wait pathway and alternative routes in the UK health system.
Wong BYW; Fischer S; Cruickshank HE
Eur Arch Otorhinolaryngol; 2017 Jan; 274(1):415-420. PubMed ID: 27416743
[TBL] [Abstract][Full Text] [Related]
27. 25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province.
Tiwana MS; Wu J; Hay J; Wong F; Cheung W; Olson RA
Oral Oncol; 2014 Jul; 50(7):651-6. PubMed ID: 24731736
[TBL] [Abstract][Full Text] [Related]
28. Role of human papillomavirus in non-oropharyngeal head and neck cancers.
Combes JD; Franceschi S
Oral Oncol; 2014 May; 50(5):370-9. PubMed ID: 24331868
[TBL] [Abstract][Full Text] [Related]
29. Is the early identification and referral of suspected head and neck cancers by community pharmacists feasible? A qualitative interview study exploring the views of patients in North East England.
Bissett SM; Sturrock A; Carrozzo M; Lish R; Howe D; Mountain S; Nugent M; O'Hara J; Todd A; Wilkes S; Preshaw PM
Health Expect; 2023 Oct; 26(5):2089-2097. PubMed ID: 37458410
[TBL] [Abstract][Full Text] [Related]
30. HPV-associated neuroendocrine carcinomas of the head and neck in FNA biopsies: Clinicopathologic features of a rare entity.
Jo VY; Krane JF; Pantanowitz L; Monaco SE
Cancer Cytopathol; 2019 Feb; 127(1):26-34. PubMed ID: 30475447
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of p16 immunocytochemistry in metastatic cervical lymph nodes in head and neck cancers.
Kapoor D; Handa U; Kundu R; Das A
Diagn Cytopathol; 2021 Apr; 49(4):469-474. PubMed ID: 33428334
[TBL] [Abstract][Full Text] [Related]
32. Earlier and more specific detection of persistent neck disease with diffusion-weighted MRI versus subsequent PET/CT after definitive chemoradiation for oropharyngeal squamous cell carcinoma.
Yu Y; Mabray M; Silveira W; Shen PY; Ryan WR; Uzelac A; Yom SS
Head Neck; 2017 Mar; 39(3):432-438. PubMed ID: 27726241
[TBL] [Abstract][Full Text] [Related]
33. p16
Brauswetter D; Birtalan E; Danos K; Kocsis A; Krenacs T; Timar J; Mihalyi R; Horcsik D; Polony G; Tamas L; Petak I
Eur Arch Otorhinolaryngol; 2017 Apr; 274(4):1959-1965. PubMed ID: 27999998
[TBL] [Abstract][Full Text] [Related]
34. Circulating cell-free DNA-based multi-cancer early detection.
Zhang K; Fu R; Liu R; Su Z
Trends Cancer; 2024 Feb; 10(2):161-174. PubMed ID: 37709615
[TBL] [Abstract][Full Text] [Related]
35. North-American survey on HPV-DNA and p16 testing for head and neck squamous cell carcinoma.
Maniakas A; Moubayed SP; Ayad T; Guertin L; Nguyen-Tan PF; Gologan O; Soulieres D; Christopoulos A
Oral Oncol; 2014 Oct; 50(10):942-6. PubMed ID: 25096827
[TBL] [Abstract][Full Text] [Related]
36. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience.
Singhi AD; Westra WH
Cancer; 2010 May; 116(9):2166-73. PubMed ID: 20186832
[TBL] [Abstract][Full Text] [Related]
37. Challenges in diagnosing head and neck cancer in primary health care.
Nieminen M; Aro K; Mäkitie A; Harlin V; Kainulainen S; Jouhi L; Atula T
Ann Med; 2021 Dec; 53(1):26-33. PubMed ID: 32746635
[TBL] [Abstract][Full Text] [Related]
38. Correlation of p16 immunostaining in cell-blocks with corresponding tissue specimens for squamous cell carcinomas of the oropharynx.
Song SJ; Jalaly JB
Cytopathology; 2021 Jan; 32(1):100-107. PubMed ID: 32886831
[TBL] [Abstract][Full Text] [Related]
39. Multi-year clinical outcomes of cancers diagnosed following detection by a blood-based multi-cancer early detection (MCED) test.
Buchanan AH; Lennon AM; Choudhry OA; Elias PZ; Rego SP; Sadler JR; Roberta J; Zhang Y; Flake DD; Salvati ZM; Wagner ES; Fishman EK; Papadopoulos N; Beer TM
Cancer Prev Res (Phila); 2024 May; ():. PubMed ID: 38819783
[TBL] [Abstract][Full Text] [Related]
40. Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes.
Romesser PB; Cahlon O; Scher ED; Hug EB; Sine K; DeSelm C; Fox JL; Mah D; Garg MK; Han-Chih Chang J; Lee NY
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):386-395. PubMed ID: 27084656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
